Scientists at Planet Biotechnology identify and develop promising antibodies and receptor/ligand-Fc fusion proteins for the treatment and prevention of disease. Planet's anti-infective programs focus on tick-borne diseases, coronaviruses, and multi-drug resistant pathogens. The Company uses a plant-based expression system to rapidly produce its antibody and receptor/ligand-Fc products.